Improving the Stability of the Directional Room G 31-33, Horizon 210 - East, Ocnele Mari-Coceneṣti Salt Mine, By Reinforcement with Anchors and Shotcrete

The rock salt deposit from Ocnele Mari - Coceneşti was mined by the method with rooms and small square pillars, at the levels + 226m and + 210m. Although the saline is not deep, certain instability phenomena (cracks, exfoliations) have occurred in the resistance structures (pillars, ceilings), especially in the G31-33 directional room, horizon 210E. These instability phenomena were also highlighted following the 3D finite element numerical modelling. In order to prevent the degradation of the mining excavations and the resistance structures, the affected surfaces were supported with anchors and reinforced shotcrete. The ceiling of the consolidated section of the G31-33 directional room, horizon 210E is monitored by the systematic measurement, on topographic landmarks mounted on the ceiling, of the vertical and horizontal displacements.

Pemetaan Keterlibatan Pemangku Kepentingan yang Berpengaruh dalam Pembangunan PLTN Pertama di Kalimantan Barat

PEMETAAN KETERLIBATAN PEMANGKU KEPENTINGAN YANG BERPENGARUH DALAM PEMBANGUNAN PLTN PERTAMA DI KALIMANTAN BARAT. Berdasarkan pedoman IAEA Nuclear Series No. NG-G.31, negara pendatang baru dalam bidang PLTN perlu mempersiapkan 19 aspek infrastruktur. Hasil reviu IAEA menyatakan bahwa di Indonesia terdapat tiga infrastruktur yang masih belum siap. Salah satu aspek tersebut adalah kesiapan keterlibatan pemangku kepentingan. Makalah ini menampilkan pemetaan pemangku kepentingan di provinsi Kalimantan Barat dan keterlibatannya dalam rencana pembangunan PLTN di Indonesia. Fokus penelitian di Kalimantan Barat sesuai dengan lokasi rencana pembangunan PLTN. Tujuan makalah adalah memetakan pihak pemangku kepentingan mana saja yang memiliki pengaruh terkuat dan tingkat keinginan tertinggi dalam pembangunan PLTN, khususnya pada tahap pengambilan keputusan dibangunnya PLTN (tahap pertama). Metode yang digunakan adalah studi literatur terkait dasar-dasar penentuan pihak yang menjadi pemangku kepentingan beserta cara analisisnya, wawancara dan diskusi dengan para narasumber yang sesuai dan ahli di bidangnya juga diskusi langsung dengan para responden, serta pembagian kuisioner kepada para responden. Selanjutnya hasil kuisioner diolah dnegan menggunakan spreadsheet dan ditampilkan dalam grafik menggunakan matriks Mendelow. Hasil evaluasi dan analisis sementara menunjukkan bahwa secara umum para pemangku kepentingan di Kalimantan Barat mempunyai pengaruh kuat dan keinginan tinggi terhadap rencana pembangunan PLTN di wilayahnya, kecuali LSM anti nuklir.

A Single-Center Phase IIa Study Evaluating the Safety and Tolerability of Umbralisib and Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Introduction: Treatment for relapsed or refractory (rel/ref) diffuse large B-cell lymphoma (DLBCL) remains an unmet medical need despite the recent approval of chimeric antigen receptor T-cell (CAR-T) therapeutic constructs. Many patients will be "too sick to CAR-T" or may have logistical/financial challenges that will not allow this treatment. As a result, non-chemotherapy agents with activity in rel/ref DLBCL require further development to help fill this need. Umbralisib (UMB) is dual PI3K delta/CK-1ε inhibitor that has single agent activity in rel/ref DLBCL with an ORR of 31% [Burris et al. 2018]. Ibrutinib (IBR) is a Bruton Tyrosine kinase (BTK) inhibitor with activity seen in the activated B-cell (ABC) subtype of DLBCL with an ORR of 37% in this subtype [Wilson et al. 2015]. Pre-clinical data (not shown) demonstrated synergistic activity of UMB-IBR against cell lines of both germinal center B-cell (GCB) and non-GCB subtypes of DLBCL. We report results of phase IIa study of the combination of UMB-IBR in rel/ref DLBCL. Methods: Eligible patients (pts) had relapsed or refractory DLBCL, ANC ≥1000 cells/mm3, platelets ≥100 K/mm3, and adequate organ function. The Hans algorithm defined cell of origin. UMB was dosed at 800 mg daily in AM and IBR 560 mg daily in PM. Treatment stratification was performed on a 1:1:1 design to Cohort A (UMB), B (IBR), or C (UMB+IBR) by consent to optional biopsies, which included optional pre-treatment and day 8 biopsies to assess pre-specified correlative flow cytometric analysis of the B-cell receptor (BCR) pathway. In cohorts A/B the combination was initiated at day 8. A cycle was 28 days. Pts received UMB-IBR for up to 1-year of therapy in the absence of progression disease (PD) or excess toxicity. The primary endpoint was monitoring for cumulative toxicity events (CTEs) occurring during cycles 1-4. A CTE was defined as grade (G) 4 neutropenia or thrombocytopenia, G3 neutropenia or thrombocytopenia last longer than 7 days, G3 non-hematologic toxicity, or any G adverse event which led to a drug hold > 7 days. Consecutive stopping rules for CTEs and efficacy were employed. Secondary endpoints included overall response rate (ORR), complete response (CR) rate, partial response (PR) rate, progression-free survival (PFS), time to response (TTR), and duration of response (DOR). Results: Thirteen pts with rel/ref DLBCL were enrolled. Median age was 71 years (range 27-81) and 9 were male. Median number of prior therapies was 2 [range 1-7] with 8% having undergone prior autologous transplantation. Sixty-two percent were refractory to last therapy. DLBCL subtypes were GCB in 7 and non-GCB in 6 pts. The first 3 pts were enrolled to Cohort C regardless of optional biopsy consent. Cohorts A (n=1) and B (n=1) included pts that consented to optional biopsies. Cohort C (n=11) included the first 3 pts enrolled into the study and those thereafter that did not consent to optional biopsies. Two CTEs were seen: G3 rash and G3 Clostridium difficile (C. diff) diarrhea. No CTEs occurred during cycle 1. Notable serious or recurrent adverse events (SAEs or AEs) of interest occurring across all cycles regardless of attribution included elevated AST/ALT 0% G 3-4 (all G 31%), nausea 15% G 3-4 (all G 54%), and diarrhea 15% G 3-4 (all G 31%). The ORR of the UBR-IBR regimen was 23% with 2 PRs (both GCB) and 1 CR (non-GCB). The pt in CR remains on treatment at 7 months and recovered from a CTE during cycle 4 (C. diff). The median PFS was 3 months [95 % CI 0.85, 3.8]. No patient was taken off study for toxicity and there were no dose reductions necessary. Conclusion: In this phase IIa study of rel/ref DLBCL, the non-chemotherapy regimen of UMB-IBR was well tolerated with only 2 CTEs and limited AEs. The evaluation of CTEs was limited by the rapid PD in many pts seen prior to 4 cycles of therapy. The ORR of the UMB-IBR was modest (23%) and of limited durability in this difficult to treat patient population. Based on limited activity and difficulty in obtaining biopsies for correlative analyses, this study was terminated prematurely. Disclosures Lunning: Portola: Consultancy; Spectrum: Consultancy; Genzyme: Consultancy; Genentech: Consultancy; Juno: Consultancy; Bayer: Consultancy; Seattle Genetics: Consultancy; Celgene: Consultancy; Astra-Zeneca: Consultancy; Genentech: Consultancy; Kite: Consultancy; AbbVie: Consultancy; Janssen: Consultancy; Gilead: Consultancy; TG Therapeutics: Consultancy; Verastem: Consultancy. Blumel:TG Therapeutics, Inc.: Consultancy. Vose:Epizyme: Honoraria; Seattle Genetics, Inc.: Research Funding; Merck Sharp & Dohme Corp.: Research Funding; Roche: Honoraria; Acerta Pharma: Research Funding; Abbvie: Honoraria; Kite Pharma: Research Funding; Legend Pharmaceuticals: Honoraria; Incyte Corp.: Research Funding; Bristol Myers Squibb: Research Funding; Novartis: Honoraria, Research Funding; Celgene: Research Funding.

Genetic divergence in Brassica rapa L.

Different multivariate analysis techniques were used to classify 33 Brassica rapa L. genotypes. The genotypes were grouped into five clusters. Cluster I contained the maximum number of genotypes. Cluster III earned the highest cluster mean value for number of primary branches/plant, number of secondary branches/plant, number of siliquae/plant and seed yield/plant. Therefore, more emphasis can be given on cluster III for selecting genotypes as parents for the hybridization program. The highest intra-cluster distance (3.822) was found in cluster I and the lowest (0.000) in cluster V. The highest inter-cluster distance (15.705) was observed between clusters III and V showing wide diversity among the groups. Principal component analysis (PCA) showed that the first three principal components accounted for 99.38 % of the total variation observed. Analysis of the factor loading of the component character indicated that the characters number of siliquae/plant, plant height and days to maturity were found responsible for genetic divergence. The role of number of siliquae/plant in both the vectors was important components for genetic divergence in these materials. Among the possible 528 combinations, the highest inter-genotypic distance (1.5975) was observed between G-27 (BARI sarisha-9 x BARI sarisha-6 S-62) and G-31 (BARI sarisha-15). Considering group and inter-genotypic distance, cluster mean, contribution of different characters towards the total divergence and other agronomic performance the genotypes G- 19 (BARI sarisha-6 x TORI-7 S-48), G-20 (F6 x BARI sarisha-9 S-52), G-27 and G-30 (BARI sarisha-6 x TORI-7 S-37) from cluster III; G-26 (F6 x BARI sarisha-9 S-15) and G-31 from cluster IV and G-33 (BARI sarisha-6) from cluster V would be considered as better parents for future hybridization program.Bangladesh J. Agril. Res. 40(3): 421-433, September 2015